Renaissance Technologies (RenTech)'s URGN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 244,300 shares of UroGen Pharma Ltd. (URGN) worth $5.72 M, representing 0.01% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in URGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 236,900 shares. Largest reduction occurred in Q3 2018, reducing 98,651 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s UroGen Pharma (URGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly UroGen Pharma (URGN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -30,800 | Reduce 11.20% | 244,300 | $23.42 |
| Q3 2025 | +236,900 | Add 620.16% | 275,100 | $19.95 |
| Q2 2025 | -52,400 | Reduce 57.84% | 38,200 | $13.70 |
| Q1 2025 | -47,600 | Reduce 34.44% | 90,600 | $11.06 |
| Q4 2024 | +138,200 | New Buy | 138,200 | $10.65 |
| Q1 2024 | -91,300 | Sold Out | 0 | $0.00 |
| Q4 2023 | -69,000 | Reduce 43.04% | 91,300 | $15.01 |
| Q3 2023 | +86,300 | Add 116.62% | 160,300 | $14.01 |
| Q2 2023 | +26,000 | Add 54.17% | 74,000 | $0.01 |
| Q1 2023 | +4,700 | Add 10.85% | 48,000 | $0.01 |
| Q4 2022 | +200 | Add 0.46% | 43,300 | $0.01 |
| Q3 2022 | -500 | Reduce 1.15% | 43,100 | $8.33 |
| Q2 2022 | +18,900 | Add 76.52% | 43,600 | $8.19 |
| Q1 2022 | +24,700 | New Buy | 24,700 | $8.70 |
| Q1 2021 | -32,800 | Sold Out | 0 | $0.00 |
| Q4 2020 | +32,800 | New Buy | 32,800 | $18.02 |
| Q2 2019 | -8,000 | Sold Out | 0 | $0.00 |
| Q1 2019 | +8,000 | New Buy | 8,000 | $37.00 |
| Q4 2018 | -16,800 | Sold Out | 0 | $0.00 |
| Q3 2018 | -98,651 | Reduce 85.45% | 16,800 | $47.20 |
| Q2 2018 | -41,249 | Reduce 26.32% | 115,451 | $49.76 |
| Q1 2018 | +25,600 | Add 19.53% | 156,700 | $49.69 |
| Q4 2017 | +105,500 | Add 412.11% | 131,100 | $37.21 |
| Q3 2017 | +25,600 | New Buy | 25,600 | $31.52 |
Renaissance Technologies (RenTech)'s UroGen Pharma Investment FAQs
Renaissance Technologies (RenTech) first purchased UroGen Pharma Ltd. (URGN) in Q3 2017, acquiring 25,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held UroGen Pharma Ltd. (URGN) for 24 quarters since Q3 2017.
Renaissance Technologies (RenTech)'s largest addition to UroGen Pharma Ltd. (URGN) was in Q3 2025, adding 275,100 shares worth $5.49 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 244,300 shares of UroGen Pharma Ltd. (URGN), valued at approximately $5.72 M.
As of the Q4 2025 filing, UroGen Pharma Ltd. (URGN) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in UroGen Pharma Ltd. (URGN) was 275,100 shares, as reported at the end of Q3 2025.